Danish company prepares to take the psoriasis market by storm – seeks FDA approval

The privately-owned company MC2 Therapeutics will launch their newly developed psoriasis treatment to the American market next year, if all goes well. The company’s product has beaten a Leo Pharma alternative when directly compared in clinical trials, and the FDA will now decide whether to approve the treatment.

"We have peace of mind, because it feels like we are doing the right things. We are constantly building up our case," says Jesper J. Lange, Administrative Drector for MC2 Therapeutics. | Photo: MC2 Therapeutics / PR

MC2 Therapeutics, which is based in Hørsholm, has quietly developed a product that could have a significant impact on the American market for psoriasis treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs